| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | FHL5; UNC18B; Hunc18b; UNC18-2; pp10122; MUNC18-2 |
| WB Predicted band size | 66 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human STXBP2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于STXBP2抗体的3篇参考文献及其摘要内容：
---
1. **文献名称**: *Mutations in STXBP2 impair cytotoxic granule exocytosis in NK cells and result in a familial hemophagocytic lymphohistiocytosis type 5*
**作者**: Côte M. et al.
**摘要**: 该研究通过基因测鉴发现STXBP2突变导致家族性噬血细胞性淋巴组织细胞增多症(FHL5)，并利用STXBP2抗体检测患者NK细胞中蛋白表达缺失，证实突变引起细胞毒性颗粒分泌缺陷。
2. **文献名称**: *Functional characterization of natural STXBP2 mutations in patients with familial hemophagocytic lymphohistiocytosis*
**作者**: zur Stadt U. et al.
**摘要**: 研究分析了FHL患者中STXBP2的突变类型，通过Western blot(使用STXBP2抗体)发现突变导致Munc18-2蛋白稳定性下降，揭示了其与免疫细胞脱颗粒功能障碍的关联。
3. **文献名称**: *Impaired cytotoxic lymphocyte degranulation in syntaxin-binding protein 2 (STXBP2)-deficient mice*
**作者**: Spessott W.A. et al.
**摘要**: 利用STXBP2基因敲除小鼠模型，结合抗体免疫染色技术，证明STXBP2缺失导致CTL细胞脱颗粒异常，为FHL5的病理机制提供了体内实验证据。
---
以上文献均聚焦于STXBP2在免疫疾病中的功能及其抗体的实验应用，涵盖临床突变分析、蛋白表达检测及动物模型研究。
The STXBP2 (Syntaxin-Binding Protein 2) antibody is a tool used to study the STXBP2 protein, a critical regulator of intracellular membrane trafficking and vesicle fusion. STXBP2. also known as Munc18-2. binds to syntaxin proteins and facilitates SNARE complex assembly, which is essential for secretory processes, including immune cell functions like cytotoxic granule exocytosis in cytotoxic T cells and natural killer (NK) cells. Dysregulation of STXBP2 is linked to familial hemophagocytic lymphohistiocytosis type 5 (FHL5), a rare, life-threatening immune disorder characterized by impaired cytotoxic granule release and hyperinflammation.
Research using STXBP2 antibodies focuses on understanding its role in immune regulation and vesicle dynamics. These antibodies are employed in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect STXBP2 expression levels, localization, and interactions in cellular and tissue samples. In clinical diagnostics, STXBP2 antibodies aid in identifying mutations or deficiencies associated with FHL5. enabling targeted genetic testing and therapeutic interventions.
The development of high-specificity STXBP2 antibodies has advanced studies on immune dysregulation mechanisms and potential therapies for FHL5. Their applications extend to exploring broader implications in immune disorders, cancer biology, and neurological conditions where vesicle trafficking defects are implicated.
×
